Arkadios Wealth Advisors Trims Holdings in SPDR S&P Biotech ETF $XBI

Arkadios Wealth Advisors reduced its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 46.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,262 shares of the exchange traded fund’s stock after selling 5,499 shares during the period. Arkadios Wealth Advisors’ holdings in SPDR S&P Biotech ETF were worth $627,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of XBI. Prime Capital Investment Advisors LLC boosted its position in shares of SPDR S&P Biotech ETF by 37.9% in the second quarter. Prime Capital Investment Advisors LLC now owns 9,939 shares of the exchange traded fund’s stock worth $824,000 after buying an additional 2,729 shares during the period. Altfest L J & Co. Inc. grew its position in shares of SPDR S&P Biotech ETF by 63.1% during the 3rd quarter. Altfest L J & Co. Inc. now owns 124,921 shares of the exchange traded fund’s stock valued at $12,517,000 after buying an additional 48,326 shares during the last quarter. Brian Low Financial Group LLC acquired a new stake in SPDR S&P Biotech ETF in the third quarter worth $668,000. AlphaCore Capital LLC raised its holdings in shares of SPDR S&P Biotech ETF by 6,650.0% during the second quarter. AlphaCore Capital LLC now owns 540 shares of the exchange traded fund’s stock valued at $45,000 after buying an additional 532 shares during the last quarter. Finally, RFG Advisory LLC acquired a new position in shares of SPDR S&P Biotech ETF during the second quarter valued at $208,000.

SPDR S&P Biotech ETF Price Performance

Shares of XBI opened at $127.86 on Tuesday. The company has a 50-day moving average of $122.86 and a two-hundred day moving average of $106.29. SPDR S&P Biotech ETF has a one year low of $66.66 and a one year high of $132.09. The stock has a market cap of $8.56 billion, a price-to-earnings ratio of 11.47 and a beta of 0.93.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.